Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection

Elion, Richard; Cohen, Calvin; Gathe, Joseph; Shalit, Peter; Hawkins, Trevor; Liu, Hui C.; Mathias, Anita; Chuck, Steven L.; Kearney, Brian P.; Warren, David R.

doi:10.1097/qad.0b013e32834b4d48

Cited by 84 publications

(76 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, similar lipid profiles were observed with atazanavir being boosted with ritonavir or cobicistat [68,69] NNRTIs have been found to increase TC and high-density lipoprotein-cholesterol (HDL-C), with an improvement of the TC/HDL ratio. In a recent study, efavirenz was associated with increases in TC, LDL-C, but not TC/HDL compared to atazanavir-ritonavir [70].…”

Section: Metabolic and Thrombotic Complications Associated With Cartsupporting

confidence: 59%

Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?

2015

View full text Add to dashboard Cite

With more effective and widespread antiretroviral treatment, the overall incidence of AIDS- or HIV-related death has decreased dramatically. Consequently, as patients are aging, cardiovascular disease (CVD) has emerged as an important cause of morbidity and mortality in the HIV population. The incidence of CVD overall in HIV is relatively low, but it is approximately 1.5-2-fold higher than that seen in age-matched HIV-uninfected individuals. Multiple factors are believed to explain this excess in risk such as overrepresentation of traditional cardiovascular risk factors (particularly smoking), toxicities associated with cumulative exposure to some antiretroviral agents, together with persistent chronic inflammation, and immune activation associated with HIV infection. Tools are available to calculate an individual's predicted risk of CVD and should be incorporated in the regular follow-up of HIV-infected patients. Targeted interventions to reduce this risk must be recommended, including life-style changes and medical interventions that might include changes in antiretroviral therapy.

show abstract

Section: Metabolic and Thrombotic Complications Associated With Cartsupporting

confidence: 59%

Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?

2015

View full text Add to dashboard Cite

show abstract

“…On the contrary, methadone levels are not affected by coadministration [16], and only minor interaction exists with buprenorphine and naloxone [17]. [20]. Ten percent (8/79) participants 26] study GS-US-236-0103 was a Phase III, double-blind, multicentre trial comparing the efficacy and safety of EVG/Cobi/TDF/ FTC to ATV/rtv plus FTC/TDF in antiretroviral-naive subjects having plasma HIV RNA ‡ 5000 copies/ml (n = 353 vs. 355).…”

Section: Drug--drug Interactionsmentioning

confidence: 98%

Cobicistat: a new opportunity in the treatment of HIV disease?

Capetti

Rizzardini

2014

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Cobi has shown good efficacy in HIV-infected treatment-naïve subjects, either in combination with ELV, within a quadruple drug, single tablet regimen, and in combination with atazanavir and darunavir. Coformulations containing cobi will mark the near future of antiretroviral therapy, therefore it will be necessary for physicians to become familiar with their management. In particular, the inhibition of creatinine secretion by the proximal renal tubule will require the acquisition of competences in estimating the real glomerular filtration rate, since studies with iohexol clearance have shown that the eGFR reduction is cosmetic. The long-term metabolic advantages of cobi versus ritonavir can be hypothesized, given the initial data from current trials.

show abstract

“…A phase II, randomized, partially placebo-controlled, double-blind, multicenter study [20] demonstrated that COBI had sustainable and comparable efficacy and safety to RTV as a pharmacoenhancer of ATV. Often it considered indifferent use ritonavir or cobicistat as enhancers, but must take into account the differences between them in terms of metabolism to predict potential interactions, especially with other drugs taken by the patient.…”

Section: Toxicity Issuesmentioning

confidence: 97%

Switching antiretroviral regimes for the treatment of HIV: safety implications

Utrillo

Vidal

Puig

et al. 2016

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Switching cART has been a popular strategy to address safety issues throughout the antiretroviral era. The myriad of switching studies have paralleled the study and release into clinical practice of new antiretroviral drugs with different and often improved safety profiles. Most of them have been successful in improving antiretroviral toxicity while keeping HIV replication under control. However, it should be taken into account that, whenever a new drug is given, there is a possibility of new drug-related toxicity. Notwithstanding that, an increase in cART switching is foreseen, given the fact that we have a wide antiretroviral drug armamentarium and that people living with HIV are ageing and thus more prone to developing age-related co-morbidities whose therapies may entail new interactions and eventually new toxicities.

show abstract

Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection

Abstract: Using cobicistat and ritonavir as pharmacoenhancers for atazanavir and administered with emtricitabine/tenofovir df achieved comparable rates of virologic suppression and CD4 cell count increase with satisfactory safety profiles.

Cited by 84 publications

References 9 publications

Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?

Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?

Cobicistat: a new opportunity in the treatment of HIV disease?

Switching antiretroviral regimes for the treatment of HIV: safety implications

Contact Info

Product

Resources

About